An observational study in Cranial Diseases (e.g., Brain Tumors, Stroke, Neurodegenerative Disorders), sponsored by Tongji Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Tongji Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies in Brain Neoplasms with a site in China — 73 open to participants now, 84 under way, 7 of them phase 3. Brain Neoplasms · China.
Among the 180 studies in Brain Neoplasms with a site in China, this one is the 11th largest by planned enrollment of the 37 observational ones that give a count, is one of 20 that started in 2026, is one of 37 observational ones, reaches primary completion later than 39 of the 83 other live ones, and was the 163rd registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →73 of the 180 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:
Beijing Inno Medicine Co., Ltd. · Sites in China, United States
Ages 18–70
Bristol-Myers Squibb · Sites in China, United States, Belgium and 10 more countries
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18–70
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 76 · Phase 3 23 · Phase 4 3
First in 1997; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 60 across the 143 interventional studies, 358 across the 37 observational. Of the 41 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 180 have an industry lead sponsor. The 10 most frequent:
Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.
Tongji Hospital has 2 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Brain Neoplasms with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT06457906Phase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesSRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | 2027-08-30 |
| NCT07446842Tongji HospitalConstruction of AI Model for Precision Imaging Diagnosis of Cranial Diseases | 2026-12 |
| NCT06231186Ruijin Hospitala Feasibility Study of iHD-SRT for BM | 2026-12 |
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 180 studies in Brain Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to develop and validate a high-precision AI diagnostic model for cranial diseases by integrating clinical knowledge systems (pathophysiological classification, age stratification, and anatomical localization) to simulate radiologists' diagnostic thinking. The main question it aims to answer is: Does the AI model improve diagnostic accuracy and consistency across different hospital levels, physician qualifications, and clinical scenarios compared to traditional diagnosis? Participants' cranial MRI data (including T1, T2, FLAIR, DWI sequences) and clinical information will be collected retrospectively (2015-2025) and prospectively (2026) to train and validate the model, which will be evaluated through performance metrics (accuracy, sensitivity, specificity) and clinical efficacy assessments (doctor vs. model, with/without model assistance). This study will establish a new paradigm for clinical AI implementation, providing methodological support for precision diagnosis of neurological diseases.
The study population will consist of patients diagnosed with the 48 specified cranial diseases from various hospitals, including neurology departments of tertiary hospitals, specialized clinics, and community medical centers. Participants will be selected based on clinical diagnosis and availability of complete cranial imaging data, ensuring representation of diverse disease types and severities for model training and validation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients clinically diagnosed with one of the following 48 cranial diseases: glioma, lymphoma, meningioma, pituitary macroadenoma, ependymoma, choroid plexus papilloma, schwannoma, medulloblastoma, tumor, chordoma, craniopharyngioma, germinoma, hemangioblastoma, cholesteatoma, teratoma, viral encephalitis, brain abscess, cerebral tuberculosis infection, cryptococcal encephalitis, cerebral cysticercosis, general soft meningitis (including bacterial, fungal infections, and meningitis), tuberculous meningitis, ischemic stroke, cerebral venous sinus thrombosis, arteriovenous malformation, cavernous hemangioma, venous developmental malformation, aneurysm, cerebral small vessel disease, epidural hemorrhage, subdural hemorrhage, intracerebral hemorrhage, cerebral contusion, subarachnoid hemorrhage, diffuse axonal injury, multiple sclerosis, hippocampal sclerosis, focal cortical dysplasia, cortical or cerebral fissure malformations, basilar invagination, Chiari malformation, Dandy-Walker malformation, Rathke's cleft cyst, pituitary hypoplasia, adrenoleukodystrophy, Alzheimer's disease, Parkinson's disease, arachnoid cyst.
Exclusion Criteria:
Patients with other severe neurological diseases not included in the 48 specified cranial diseases; Patients unable to provide complete cranial imaging data (e.g., missing images or images of poor quality); Patients with severe cognitive impairment unable to cooperate with the study (e.g., unable to understand study procedures or communicate with site personnel); Pregnant or lactating women; Patients with severe dysfunction of major organs (e.g., heart, liver, kidney) that cannot tolerate study-related examinations; Patients who refuse to sign the form.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
including 70,000 unsupervised training cases and 2,000 supervised training cases for model development.
Prospective data collection from March 1, 2026 to December 31, 2026, including 1,000 cases for model validation and clinical efficacy evaluation.
Diagnostic accuracy of AI model (sensitivity, specificity, AUC)
The primary outcome is the diagnostic performance of the AI model, including sensitivity, specificity, and area under the ROC curve (AUC), compared to the gold standard (e.g., histopathology or clinical diagnosis).
Time frame: Within 1 month of image acquisition
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 11 months is below that.
Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.